Data from a recent prospective study43 assessing the effect of a germline BRCA1 or BRCA2 mutation on breast cancer outcomes in patients with young-onset breast cancer found that this group (tested positive for BRCA1 or BRCA2) had similar survival compared to non-carriers. This evidence concerns the gene BRCA1 and breast carcinoma.